Eptacog Alfa Market

Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:

1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.

Eptacog Alfa Market aims to provide a comprehensive presentation of the global market for Eptacog Alfa (rFVIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (rFVIIa). Eptacog Alfa Market contains market size and forecasts of Eptacog Alfa (rFVIIa) in global, including the following market information:

Global Eptacog Alfa (rFVIIa) Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global Eptacog Alfa (rFVIIa) Market Sales, 2018-2023, 2024-2029, (g)

Global top five Eptacog Alfa (rFVIIa) companies in 2022 (%)

The global Eptacog Alfa (rFVIIa) market was valued at US$ 1224.5 million in 2022 and is projected to reach US$ 1655.4 million by 2029, at a CAGR of 4.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.

We surveyed the Eptacog Alfa (rFVIIa) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Eptacog Alfa (rFVIIa) Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (g)

Global Eptacog Alfa (rFVIIa) Market Segment Percentages, by Type, 2022 (%)

Freeze-dried Preparation

Freeze-dried Powder

Global Eptacog Alfa (rFVIIa) Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (g)

Global Eptacog Alfa (rFVIIa) Market Segment Percentages, by Application, 2022 (%)

Hemophilia

Acquired Hemophilia

Factor VII Deficiency

Glanzmann Thrombasthenia (GT)

Global Eptacog Alfa (rFVIIa) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (g)

Global Eptacog Alfa (rFVIIa) Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Eptacog Alfa (rFVIIa) revenues in global market, 2018-2023 (Estimated), ($ millions)

Key companies Eptacog Alfa (rFVIIa) revenues share in global market, 2022 (%)

Key companies Eptacog Alfa (rFVIIa) sales in global market, 2018-2023 (Estimated), (g)

Key companies Eptacog Alfa (rFVIIa) sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novo Nordisk

LFB SA

GENERIUM

Northland-bio

CSL

Shire (Takeda)

Bayer

Outline of Major Chapters:

Chapter 1: Introduces the definition of Eptacog Alfa (rFVIIa), market overview.

Chapter 2: Global Eptacog Alfa (rFVIIa) market size in revenue and volume.

Chapter 3: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Global Eptacog Alfa (rFVIIa) capacity by region & country.

Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 11: The main points and conclusions of the report.